CGT4255

· Cogent Biosciences, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CGT4255, covering 2026-02-27 to 2026-02-27. Get the full timeline:

Most recent: Clinical Trial Update: A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors [Phase 1]